MDR-Tuberkulose, Alpha-1-Antitrypsin-Mangel, Husten bei Altenpflegerin

Zusammenfassung

Multiresistente Tuberkulosen (MDR-TB) machen zwar einen nur geringen Anteil an der Gesamtzahl aller TB-Erkrankungen aus, durch die erforderliche komplexe Medikation mit potenziell schweren und lebensbedrohlichen Nebenwirkungen, Langzeitfolgen und ungünstigem Verlauf ist jedoch besondere Sorgfalt geboten. Wir berichten über eine 30-jährige Altenpflegerin mit chronischem Husten und angeborenem Alpha-1-Antitrypsin-Mangel (AATM), die an einer MDR-TB erkrankte und erhebliche Medikamenten-Nebenwirkungen erlitt.

Abstract

Multidrug-resistant tuberculosis (MDR-TB) is of low proportion in comparison to the total number of TB patients, however, due to the necessity of a complex medication with potentially severe and life threatening adverse reactions, long term sequelae, and unfavorable outcome special attention is essential. We report the case of a 30-year-old geriatric nurse with a history of chronic cough and hereditary alpha-1-anti-trypsin deficiency (AATD), who suffered from MDR-TB and experienced a number of severe adverse reactions.

• Literatur

• 1 Lange C, Dheda K, Chesov D. et al. Management of drug-resistant tuberculosis. Lancet 2019; 394: 953-966
• 2 WHO. Global tuberculosis report 2018. Geneva, Switzerland: World Health Organization; 2018
• 3 Otto-Knapp R, Häcker B, Bauer T. et al. Tuberkulose – Die neuen WHO-Empfehlungen für schnelle Diagnostik und Behandlung. InFo Pneumologie & Allergologie 2020; 3: 6-11
• 4 Otto-Knapp R, Knappik M, Häcker B. et al. Die neuen WHO-Empfehlungen für schnelle Diagnostik und Therapie resistenter Tuberkulose in Deutschland, Österreich und der Schweiz. Pneumologie 2020; 74: 742-749
• 5 Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2018. Berlin: Robert Koch-Institut; 2019
• 6 Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2019. Berlin: Robert Koch-Institut; 2020
• 7 Jahresbericht 2018. Nationale Referenzzentrale für Tuberkulose: Österreichische Agentur für Gesundheit und Ernährungssicherheit (AGES); 2019
• 8 Schaberg T. et al. S2k-Leitlinie: Tuberkulose im Erwachsenenalter. Eine Leitlinie zur Diagnostik und Therapie, einschließlich Chemoprävention und -prophylaxe des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose e.V. im Auftrag der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. Pneumologie 2017; 71: 325-397
• 9 Seidler A, Nienhaus A, Diel R. Review of epidemiological studies on the occupational risk of tuberculosis in low-incidence areas. Respiration 2005; 72: 431-446
• 10 Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferongamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012; 142: 63-75
• 11 Dulon M, Lisiak B, Wendeler D. et al. Berufsbedingte Infektionskrankheiten bei Beschäftigten im Gesundheitsdienst 2014. Zbl Arbeitsmed 2015; 65: 210-216
• 12 Schaberg T, Bauer T, Castell S. et al. Empfehlungen zur Therapie, Chemoprävention und Chemoprophylaxe der Tuberkulose im Erwachsenen- und Kindesalter. Pneumologie 2012; 66: 133-171
• 13 World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis – 2011 update. 2011. 6. ed. WHO/HTM/TB/2011
• 14 Falzon D, Jaramillo E, Schunemann HJ. et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528
• 15 Bottasso O, Bay ML, Besedovsky H. et al. Immunoendocrine alterations during human tuberculosis as an integrated view of disease pathology. Neuroimmunomodulation 2009; 16: 68-77
• 16 Bottasso O, Bay ML, Besedovsky H. et al. The immune-endocrine-metabolic unit during human tuberculosis. Current Immunol Rev 2010; 6: 314-322
• 17 Santucci N, DʼAttilio L, Besedovsky H. et al. A clinical correlate of the dysregulated immunoendocrine response in human tuberculosis. Neuroimmunomodulation 2010; 17: 184-187
• 18 Santucci N, DʼAttilio L, Kovalevski L. et al. A multifaceted analysis of immune-endocrine-metabolic alterations in patients with pulmonary tuberculosis. PLoS One 2011; 6 (10) e26363
• 19 Bottasso O, Bay ML, Besedovsky H. et al. Adverse neuro-immune-endocrine interactions in patients with active tuberculosis. Mol Cell Neurosci 2013; 53: 77-85
• 20 DʼAttilio L, Díaz A, Fernández RDV. et al. The neuro-endocrine-immune relationship in pulmonary and pleural tuberculosis: a better local profile in pleural fluid. Int J Tuberc Lung Dis 2018; 22: 321-327
• 21 Díaz A, Bongiovanni B, DʼAttilio L. et al. The clinical recovery of tuberculosis patients undergoing specific treatment is associated with changes in the immune and neuroendocrine responses. Pathog Dis 2017; 75
• 22 Mase SR, Ramsay A, Ng V. et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2007; 11: 485-495
• 23 WHO. Operational handbook on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Geneva: World Health Organisation; 2020
• 24 Conradie F, Diacon AH, Ngubane N. et al. Nix-TB Trial Team. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med 2020; 382: 893-902
• 25 Nunn AJ, Phillips PPJ, Meredith SK. et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med 2019; 380: 1201-1213
• 26 Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74: 839-854
• 27 Lange C, Abubakar I, Alffenaar JW. et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63
• 28 Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO
• 29 Olaru ID, Heyckendorf J, Andres S. et al. Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1700742
• 30 Heyckendorf J, van Leth F, Kalsdorf B. et al. Relapse-free cure from multidrug-resistant tuberculosis in Germany. Eur Respir J 2018; 51: 1702122
• 31 WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organisation; 2019
• 32 WHO Consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organisation; 2020
• 33 Maurer FP, Bauer T, Diel R. et al. Gemeinsame Stellungnahme zur neuen Empfehlung der WHO zur Behandlung der multiresistenten und Rifampicin-resistenten Tuberkulose. Pneumologie 2019; 73: 270-273
• 34 Gillespie SH, Crook AM, McHugh TD. et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371: 1577-1587
• 35 Jindani A, Harrison TS, Nunn AJ. et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371: 1599-1608
• 36 Merle CS, Fielding K, Sow OB. et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014; 371: 1588-1598
• 37 Helgren ME, Cliffer KD, Torrento K. et al. Neurotrophin-3 administration attenuates deficits of pyridoxine-induced large-fiber sensory neuropathy. J Neurosci 1997; 17: 372-382
• 38 Vrolijk MF, Opperhuizen A, Jansen EHJM. et al. The vitamin B6 paradox: Supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function. Toxicol In Vitro 2017; 44: 206-212
• 39 Lan Z, Ahmad N, Baghaei P. et al. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med 2020; 8: 383-394
• 40 Merkblatt zur BK Nr. 3101: Infektionskrankheiten, wenn der Versicherte im Gesundheitsdienst, in der Wohlfahrtspflege oder in einem Laboratorium tätig oder durch eine andere Tätigkeit der Infektionsgefahr in ähnlichem Maße besonders ausgesetzt war. Merkblatt für die ärztliche Untersuchung (Bek. des BMA v. 1.12.2000, BArbBl. 1/2001, S. 35).
• 41 Dummer J, Dobler CC, Holmes M. et al. Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand. Respirology 2020; 25: 321-335
• 42 Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 2009; 360: 2749-2757
• 43 McElvaney NG, Stoller JK, Buist AS. et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111: 394-403
• 44 Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax 2004; 59: 441-445
• 45 Eden E, Hammel J, Rouhani FN. et al. Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. Chest 2003; 123: 765-771
• 46 Demeo DL, Sandhaus RA, Barker AF. et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax 2007; 62: 806-813
• 47 Greulich T, Nell C, Herr C. et al. Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003–2015. Orphanet J Rare Dis 2016; 11: 75
• 48 Makino S, Chosy L, Valdivia E. et al. Emphysema with hereditary alpha-1 antitrypsin deficiency masquerading as asthma. J Allergy 1970; 46: 40-48
• 49 Propst T, Vogel W, Dietze O. et al. Primary hepatic tuberculosis in homozygous alpha-1-antitrypsin deficiency. Ital J Gastroenterol 1992; 24: 126-128
• 50 Habibzadeh S, Shahi JM, Ghobadi H. et al. The first report of two cases of fatal liver injury due to anti-tuberculosis drugs in the presence of alpha-1 antitrypsin deficiency. Int J Mycobacteriol 2017; 6: 187-190